Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CollaGenex (CGPI) FDA PENDING -- Ignore unavailable to you. Want to Upgrade?

To: Rich H who wrote (72)	2/20/2000 8:45:00 PM
From: Jack Hartmann	Respond to of 142

I thought it was profitaking. No insiders selling so drop is not that. Many who bought in September during the record 2.5M volume day are probably taking profits off the table. Chart is ugly now so I'm watching it go down from my buy in the $24 area. Fundemantals haven't changed, only the price. Jack

To: Rich H who wrote (72)	2/21/2000 9:34:00 AM
From: biowa	Read Replies (1) \| Respond to of 142

Rich, FWIW, it may just be that the co. doesn't really have anything that's sexy now (i.e., no genomics, no gt, no mAbs). Metastat may provide some upside sizzle, but right now I give it zero valuation and I think the co. is being very conservative since it lies outside the main focus. What the company is doing is very effectively (IMO) going about its business of selling Periostat and steadily (and rapidly) growing those sales, as well as adding to the clinical support for uses. On top of this, they're building a highly effective dental pharmaceutical sales force that will probably add additional products this year to a bag that already includes Periostat, Vioxx and Denavir. In other words, they're growing revenues. biowa